Promising coronavirus vaccine trial resumes after illness forces suspension

Promising coronavirus vaccine trial resumes after illness forces suspension
Promising coronavirus vaccine trial resumes after illness forces suspension

Thank you for your reading and interest in the news Promising coronavirus vaccine trial resumes after illness forces suspension and now with details

Hind Al Soulia - Riyadh - International drugs manufacturer AstraZeneca and Oxford University have resumed a coronavirus vaccine trial after an investigation into how a volunteer developed an unexplained illness.

The AZD1222 project is one of the most promising of the potential vaccines in development and one of the furthest along the safety and efficacy testing programme.

"Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority that it was safe to do so," the company said in a statement.

"The standard review process triggered a voluntary pause to vaccination across all global trials to allow review of safety data by independent committees, and international regulators," AstraZeneca said.

"The UK committee has concluded its investigations and recommended to the MHRA that trials in the UK are safe to resume."

The company said it could not disclose further medical information.

"All trial investigators and participants will be updated with the relevant information and this will be disclosed on global clinical registries, according to the clinical trial and regulatory standards," the company said.

The New York Times has reported that a UK volunteer was found to have transverse myelitis, an inflammatory syndrome that affects the spinal cord and is often sparked by viral infections. The volunteer is expected to recover.

The potential vaccine is in its phase three trials, which focus on the effectiveness of vaccines in protecting against infection, testing thousands of volunteers in the UK, Brazil and some other countries.

In the United States, the company started enrolling the first of 30,000 volunteers on August 31.

The AZD1222 vaccine uses a weakened version of a common cold-causing adenovirus engineered to code for the spike protein that the Covid-19 coronavirus uses to invade cells.

It is one of nine currently in Phase 3 trials.

Updated: September 12, 2020 07:05 PM

These were the details of the news Promising coronavirus vaccine trial resumes after illness forces suspension for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.

It is also worth noting that the original news has been published and is available at The National and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.

PREV On an election campaign trip in one of the tipping states...
NEXT Osteoporosis … a list of foods that cause a crisis and...